Ceritinib-d_7

Cat. No.: HY-15656S

CAS No.: 1632484-77-5

Molecular Formula: $C_{28}H_{29}D_7ClN_5O_3S$

Molecular Weight: 565.18

Target: Anaplastic lymphoma kinase (ALK); Insulin Receptor; IGF-1R; Isotope-Labeled Compounds

Pathway: Protein Tyrosine Kinase/RTK; Others

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 12.5 mg/mL (22.12 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.7693 mL	8.8467 mL	17.6935 mL
5 mM	0.3539 mL	1.7693 mL	3.5387 mL
10 mM	0.1769 mL	0.8847 mL	1.7693 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Ceritinib-d_7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

REFERENCES

[1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA